Effect of Eritoran, an Antagonist of MD2-TLR4, on Mortality in Patients With Severe Sepsis-Reference-Cited by-同舟云学术

Effect of Eritoran, an Antagonist of MD2-TLR4, on Mortality in Patients With Severe Sepsis

Published:2013-03-20 Issue:11 Volume:309 Page:1154
ISSN:0098-7484
Container-title:JAMA
language:en
Short-container-title:JAMA

Author:

Opal Steven M.,Laterre Pierre-Francois,Francois Bruno,LaRosa Steven P.,Angus Derek C.,Mira Jean-Paul,Wittebole Xavier,Dugernier Thierry,Perrotin Dominique,Tidswell Mark,Jauregui Luis,Krell Kenneth,Pachl Jan,Takahashi Takeshi,Peckelsen Claus,Cordasco Edward,Chang Chia-Sheng,Oeyen Sandra,Aikawa Naoki,Maruyama Tatsuya,Schein Roland,Kalil Andre C.,Van Nuffelen Marc,Lynn Melvyn,Rossignol Daniel P.,Gogate Jagadish,Roberts Mary B.,Wheeler Janice L.,Vincent Jean-Louis,ACCESS Study Group for the

Publisher

American Medical Association (AMA)

Subject

General Medicine

Cited by 653 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neonatal bacteremia and sepsis;Remington and Klein's Infectious Diseases of the Fetus and Newborn Infant;2025

2. Mechanisms of food-derived bioactive compounds inhibiting TLR4 activation and regulating TLR4-mediated inflammation: A comprehensive review and future directions;Food Bioscience;2024-10

3. Metabolic reprogramming in septic acute kidney injury: pathogenesis and therapeutic implications;Metabolism;2024-09

4. Nonreducing Sugar Scaffold Enables the Development of Immunomodulatory TLR4‐specific LPS Mimetics with Picomolar Potency;Angewandte Chemie International Edition;2024-08-21

5. Nonreducing Sugar Scaffold Enables the Development of Immunomodulatory TLR4‐specific LPS Mimetics with Picomolar Potency;Angewandte Chemie;2024-08-21